New Data Could Boost Potential Approval of Zogenix's Epilepsy Drug

New Data Could Boost Potential Approval of Zogenix's Epilepsy Drug

Source: 
BioSpace
snippet: 

Shares of Zogenix are climbing this morning after the California-based company posted new positive data for its investigational drug Fintepla in Dravet syndrome, a rare type of epilepsy. The new data could boost the company’s chances of securing regulatory approval.